brodalumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	5179	1174395-19-7

Description:

Molecule	Description
Synonyms: kyntheum brodalumab AMG 827 AMG-827	Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

kyntheum
brodalumab
AMG 827
AMG-827

Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
15	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
July 17, 2017	EMA	LEO Pharma A/S
Feb. 15, 2017	FDA	VALEANT LUXEMBOURG
July 4, 2016	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Collagen-vascular disease	61.76	35.89	8	794	96	63488124
Parakeratosis	53.42	35.89	8	794	287	63487933
Psoriatic arthropathy	47.24	35.89	23	779	91497	63396723
Seborrhoeic dermatitis	42.75	35.89	8	794	1113	63487107
Cutaneous T-cell lymphoma	41.09	35.89	8	794	1372	63486848
Psoriasis	39.36	35.89	20	782	86937	63401283

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriatic arthropathy	99.44	40.59	33	1056	19765	34936077
Dermatitis infected	61.66	40.59	9	1080	104	34955738
Therapy interrupted	49.93	40.59	18	1071	13679	34942163
Psoriasis	49.17	40.59	24	1065	38788	34917054
Tinea pedis	49.11	40.59	11	1078	1498	34954344
Peripheral venous disease	42.80	40.59	11	1078	2677	34953165
Arthralgia	40.68	40.59	37	1052	170004	34785838

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriatic arthropathy	87.95	31.58	41	1867	77958	79664522
Psoriasis	79.58	31.58	40	1868	89547	79652933
Parakeratosis	59.70	31.58	10	1898	384	79742096
Collagen-vascular disease	57.52	31.58	8	1900	85	79742395
Dermatitis infected	55.12	31.58	9	1899	295	79742185
Tinea pedis	52.00	31.58	12	1896	2428	79740052
Drug ineffective	51.79	31.58	92	1816	1080821	78661659
Suicidal ideation	45.03	31.58	26	1882	76314	79666166
Patient dissatisfaction with treatment	44.54	31.58	7	1901	179	79742301
Therapy interrupted	43.25	31.58	19	1889	31322	79711158
Pustule	32.92	31.58	8	1900	2017	79740463
Seborrhoeic dermatitis	32.73	31.58	8	1900	2065	79740415

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC12	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA CS	M0001357	Antibodies, Monoclonal
MeSH PA	D003879	Dermatologic Agents
FDA EPC	N0000193276	Interleukin-17 Receptor A Antagonist
FDA MoA	N0000193279	Interleukin 17 Receptor A Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Plaque psoriasis	indication	200965009
Non-radiographic axial spondyloarthritis	indication	713777005
Crohn's disease	contraindication	34000006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-17 receptor	Membrane receptor	Q96F46 Q8NAC3	I17RA_HUMAN I17RC_HUMAN	ANTIBODY BINDING	Kd	9.20		IUPHAR	SCIENTIFIC LITERATURE

External reference:

ID	Source
6ZA31Y954Z	UNII
4036541	VANDF
C3491331	UMLSCUI
CHEMBL1742996	ChEMBL_ID
D10061	KEGG_DRUG
DB11776	DRUGBANK_ID
9475	INN_ID
7540	IUPHAR_LIGAND_ID
1872251	RXNORM
32390	MMSL
d08529	MMSL
017103	NDDF
726519005	SNOMEDCT_US
763604008	SNOMEDCT_US
C571216	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Siliq	HUMAN PRESCRIPTION DRUG LABEL	1	0187-0004	INJECTION	210 mg	SUBCUTANEOUS	BLA	27 sections
Siliq	HUMAN PRESCRIPTION DRUG LABEL	1	0187-0004	INJECTION	210 mg	SUBCUTANEOUS	BLA	27 sections